ArticleMolecular and clinical oncology2016
Control of cervical cancer in Peru: Current barriers and challenges for the future.
Article in Molecular and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Prevalence and persistence of high-risk HPV genotypes in unvaccinated asymptomatic women: a six-year study in Peru.BMC research notes · 2026Article
- Article
- Prevalence of coinfections in a cross-sectional cohort of women screened for multiple pathogens in Peru.Heliyon · 2023Article
- Cost of community-based human papillomavirus self-sampling in Peru: A micro-costing study.Lancet regional health. Americas · 2022Article
- Evaluation of Women's Empowerment in a Community-Based Human Papillomavirus Self-Sampling Social Entrepreneurship Program (Hope Project) in Peru: A Mixed-Method Study.Frontiers in public health · 2022Article
- High Prevalence of Human Papillomavirus Type 18 in Oral Potentially Malignant Disorders in Thailand.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Genotype-specific prevalence of human papillomavirus infection in asymptomatic Peruvian women: a community-based study.BMC research notes · 2021Article
- Cervical cancer mortality in Peru: regional trend analysis from 2008-2017.BMC public health · 2021Article
- Variations in cervico-vaginal microbiota among HPV-positive and HPV-negative asymptomatic women in Peru.BMC research notes · 2021Article
- Article
- Policy Considerations to Promote Equitable Cervical Cancer Screening and Treatment in Peru.Annals of global health · 2021Review
- Barriers to the uptake of cervical cancer services and attitudes towards adopting new interventions in Peru.Preventive medicine reports · 2020Article
- Knowledge of Cervical Cancer Prevention Among Women in Amazonian Peru.Women's health reports (New Rochelle, N.Y.) · 2020Article
- Socio-demographic inequalities in the uptake of Papanicolaou tests in Peru: analysis of the 2015-2017 Demographic and Family Health Survey.Epidemiology and health · 2020Article
- Inequities in cervical cancer care in indigenous Peruvian women.The Lancet. Global health · 2019Article
- Comparative study of HPV and Cervical Cancer Knowledge and Beliefs between Mexican Immigrant Women in the US and Peruvian Women.Cancer health disparities · 2019Article
- Building a Network of Health Professionals for Breast and Cervical Cancer Control in the Andean Region.Journal of global oncology · 2018Article
- Frequency and coinfection between genotypes of human papillomavirus in a population of asymptomatic women in northern Peru.BMC research notes · 2018Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is the leading malignant neoplasm in Peruvian women. This malignancy is a public health problem and several efforts were previously performed to develop cancer control plans. Geographical, cultural, structural, infrastructural and procedural barriers can limit the implementation of such strategies. Several previous studies have characterized human papilloma virus (HPV) epidemiology, where prevalence of high-risk HPV in adult females is ~12% and the prevalence in cervical cancer is 90-95%. The predominant barriers for the control of cervical cancer are lack of specialists in remote villages, education/cultural issues, loss of patients in follow-up, lack of access to HPV testing and lack of compliance for HPV vaccination. A good strategy for the prevention and early detection of high-risk HPV, pre-malignant neoplasms and cervical cancer, identified by interventional studies, is the self-sampling test, which assists with overcoming the cultural and geographic barriers. The current cancer control plan, termed 'Plan Esperanza', is performed with massive training of health professionals and social sensitization campaigns leading to filling the gaps regarding education and, in addition, it provides cancer care coverage for poorer individuals. In our experience at Oncosalud-AUNA, with a cohort of ~750,000 affiliates using a pre-paid system with annual screenings for cervical cancer for women, offered free-of-charge, a lower incidence of this malignancy (5.8/100,000) is now observed compared with the national incidence (32.7/100,000). As in other countries, the HPV vaccination can be a cost-utility strategy to reduce the high burdens of cervical cancer in Peru, a rapid and cheap HPV molecular sub-typification is rapidly required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.